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The central portion of the midbody, a cytoplasmic bridge between nascent daughter cells 
at the end of cell division, has generally been thought to be retained by one of the daughter 
cells,  but  has,  recently,  also  been  shown  to  be  released  into  the  extracellular  space.  The 
significance of midbody-retention versus -release is unknown. Here we show, by quantitatively 
analysing midbody-fate in various cell lines under different growth conditions, that the extent 
of midbody-release is significantly greater in stem cells than cancer-derived cells. Induction 
of cell differentiation is accompanied by an increase in midbody-release. Knockdown of the 
endosomal sorting complex required for transport family members, Alix and tumour-suppressor 
gene 101, or of their interaction partner, centrosomal protein 55, impairs midbody-release, 
suggesting mechanistic similarities to abscission. Cells with such impaired midbody-release 
exhibit enhanced responsiveness to a differentiation stimulus. Taken together, midbody-release 
emerges as a characteristic feature of cells capable of differentiation. 
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T
he midbody is a transient structure formed during cytokine-
sis in animal cells by the ingression of the cleavage furrow1–4. 
It constitutes a cytoplasmic bridge between the two nascent 
daughter cells that contains the remnants of the central spindle and 
the contractile ring5,6. The central part of the midbody, also called 
Flemming  body,  is  characterized  by  a  morphologically  distinct, 
electron-dense matrix7–9. Abscission, which completes cell division, 
severs the midbody-bridge, bypassing its central matrix. Conse-
quently, the post-abscission midbody with its characteristic matrix 
is inherited asymmetrically by one of the daughter cells10–12.
Until recently, the canonical view was that the post-abscission 
midbody  remains  associated  with  the  cell  that  inherited  it4,11–13. 
This view has largely been based on the observation of intracellular 
midbodies in cells in culture, often referred to as ‘midbody rings’ 
because of their appearance on analysis of certain midbody mark-
ers11,14,15. These internalized post-abscission midbody structures are 
eventually degraded by autophagy15.
However, studies on the neuroepithelium in vivo have recently 
revealed an alternative fate of the midbody after cell division, that 
is, its release into the extracellular fluid16–18. This post-abscission 
route of the midbody constitutes an irreversible disposal of both, 
the cytoplasmic and membraneous midbody components from the 
cell, which is not necessarily true in the case of intracellular degra-
dation. In this context, it is noteworthy that not only components 
of the cytoskeleton such as central spindle and contractile ring con-
stituents, but also certain membrane components become concen-
trated at the midbody during cell division. For example, the five-
transmembrane-domain protein prominin-1 (CD133)19–21, a marker 
of many somatic stem cells and cancer stem cells22–24, is clustered 
at the central part of the midbody-bridge in neuroepithelial and 
haematopoietic stem and progenitor cells17,25, and has been shown 
to be released from neuroepithelial cells along with midbodies at 
the onset of neurogenesis in vivo16,17. Thus, the possibility arises that 
midbody-release may be associated with changes in cell fate.
The existence of midbody-release as an alternative pathway to 
intracellular degradation of post-abscission midbodies raises three 
key questions. First, how is midbody-release related to abscission? 
Second, how do cell types that dispose of midbodies predominantly 
by release differ from cell types that predominantly degrade midbod-
ies intracellularly? Third, what is the functional significance of mid-
body-release? Here we have addressed these questions by studying 
midbody-release versus -retention in various cell types and growth 
conditions in vitro. We find that midbody-release was greater in stem 
than  cancer  cells,  and  that  induction  of  differentiation  enhanced   
midbody release, and we conclude that midbody release may be a   
feature of cells that have the ability to commit to differentiation.
Results
Midbody-release  differs  between  cell  lines.  To  explore  how 
widespread a phenomenon midbody-release is, we subjected the 
conditioned medium of various cell lines (Supplementary Table S1) 
to a previously established differential centrifugation protocol16, and 
analysed the resulting four pellets (P1–P4) by immunoblotting for 
markers of the central region of the midbody, citron rho-interacting 
kinase  (CRIK)26,27  and  mitotic  kinesin-like  protein-1  (MKLP-1)28 
(Fig. 1). In the case of the mouse neural stem cell lines NS-5 and 
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Figure 1 | Release of membrane particles containing midbody markers from various cell types. Cell lines were grown to subconfluency over a period 
corresponding to two doubling times, and HsCs were grown for 5 days on msCs, to condition the respective culture medium. Conditioned media 
were subjected to differential centrifugation to obtain the P1, P2, P3 and P4 (except for HsCs) pellets. Immunoblots of cell lines (a,b) and of HsCs 
(c–f) (C, 1/20 of total), and of the corresponding pellets (1/2 of total), for CRIK (a,c,e) and mKLP-1 (b,d,f; same blots as in (a,c,e), respectively, after 
re-probing). molecular weight markers are indicated. Quantification of CRIK (g) and mKLP-1 (h) immunoreactivity in the P1 (dark grey), P2 (medium 
grey) and P3 (light grey) pellets of the indicated cell types, expressed as percentage of total (sum of cells plus P1–4). Data are the mean of three 
independent experiments, triplicates or quadruplicates (HsCs); bars indicate s.d. Cell types are sorted from left to right in the order of decreasing CRIK 
immunoreactivity in P1-3. *P ≤ 0.05, student’s t-test cancer/immortalized cells versus stem cells. CRIK-positive P1-3 particle release between the group 
of the four stem cells versus ten cancer-derived cells (P-value 0.0005, student’s t-test). (i) CRIK immunoblots of conditioned media of ns-5 cells plated 
on 6-well plates or 10-cm dishes. The proportion of cells (C) and P1-P4 pellets loaded are indicated. (j) Quantification of CRIK immunoreactivity of the 
immunoblots shown in (i). The sum of the pellets (P1–4) is expressed as percentage of total (sum of cells plus P1–P4).ARTICLE     
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CGR8-NS29 and the mouse embryonic stem (ES) cell line R1 (ref. 30),   
this revealed a peak of midbody marker-containing particles in the 
P2 (1,200 g, 20 min) pellet (Fig. 1a,b), reminiscent of the midbody-
derived P2 particles present in the P2 pellet obtained from mouse 
embryonic ventricular fluid16,17. To investigate whether midbody-
release  can  also  be  observed  in  primary  somatic  stem  cells,  we 
analysed human haematopoietic stem cells (HSCs) isolated from 
blood samples of healthy donors. Indeed, also for HSCs, grown either 
on a mesenchymal stromal cell (MSC) feeder layer or on fibronectin-
coated dishes, a peak of midbody marker-containing particles was 
observed in the P2 pellet, indicative of midbody-release (Fig. 1c–f).
In contrast, in the case of the tumour-derived Neuro-2a, P-19 
and SH-SY5Y cells, the midbody-marker-containing particles in the 
conditioned medium were largely recovered in the P1 (300 g, 5 min) 
pellet (Fig. 1a,b), indicative of a larger size and/or higher density of 
these particles (referred to as P1 particles). In the case of the mam-
mary cancer-derived MCF-7 cells and the mammary gland-derived 
immortalized  MCF-10A  cells,  particles  containing  MKLP-1  but   
little CRIK were largely recovered in both the P1 and P2 pellets   
(Fig.  1a,b).  Negligible  amounts  of  midbody  marker-containing   
particles were detected in the conditioned medium of various other 
cancer-derived or immortalized cell lines such as HeLa, NIH-3T3, 
CHO, HEK293 and L929 cells (Fig. 1a,b).
We quantified the amount of midbody markers released in par-
ticulate form into the culture medium (sum of P1–P4 pellets) after 
conditioning for a standardized period of time, taking into account 
the different growth rates of the cell lines studied. This revealed that, 
relative to the entire culture dish (cells plus conditioned medium), 
the  extent  of  midbody-marker-containing  particles  released  into 
the medium was strikingly different between the various cell lines 
(Fig. 1g,h). Interestingly, it was substantially greater for the three 
stem cell lines NS-5, CGR8-NS and ES-R1 and for HSCs than for 
the tumour-derived cell lines Neuro-2a, P-19, SH-SY5Y and MCF-
7 and the immortalized cell line MCF-10A. Release of CRIK-con-
taining particles for the apparently non-releasing HeLa, 3T3, CHO, 
HEK293 and L929 cells was  < 1%. The extent of release of midbody-
marker-containing particles was essentially unaffected by the size 
of the culture dishes used, as observed for NS-5 cells (Fig. 1i,j) and 
HeLa cells analysed for CRIK.
As described in Supplementary Note S1, the midbody-derived 
extracellular membrane particles in the P1 and P2 pellets were fur-
ther characterized with regard to their sedimentation properties 
using velocity sucrose density gradient centrifugation (Fig. 2) and 
their abundance and morphology by immunofluorescence (Fig. 3).
Midbody-retention varies between cell lines. The number of mid-
bodies formed reflects the rate of cell proliferation. We investigated 
the extent of midbody-retention in some of the cell lines to explore 
whether it correlates inversely with midbody-release. Immunoflu-
orescence for CRIK (Fig. 4a) and MKLP-1 (Fig. 4b) revealed that 
the proportion of cells with immunoreactive puncta, suggestive of 
cell-associated midbodies, was greater for HeLa cells, which showed 
very little midbody-release (Fig. 1), than NS-5 cells, which exhib-
ited a high extent of midbody-release (Figs 1 and 3). Neuro-2a cells 
displayed an intermediate number of residual midbodies per cell, 
consistent with the intermediate level of midbody-release (Figs 1 
and  3).  Quantification  of  cell-associated  CRIK-immunostained 
midbodies in six of the cell lines analysed for midbody-release in 
Figure 1 indicated that the average number of residual midbodies 
per cell ranged from 0.1 to 0.5 (Fig. 4c), with the values for NS-5 
(0.1) and HeLa (0.4) cells being consistent with an inverse correla-
tion between midbody-release and retention in these cells (Supple-
mentary Note S2 for the other cell lines).
The quantification of the average number of residual midbodies 
per cell (Fig. 4c) had been carried out with exponentially growing 
cells. This allowed us to relate the extent of midbody-retention to 
cell growth rates. However, no correlation between residual mid-
body number and cell doubling time was observed for the six cell 
lines analysed (Fig. 4c).
Low midbody levels in NS-5 cells are not due to autophagy. It 
has previously been shown that the level of residual midbodies in 
cells is increased on inhibition of autophagy by drugs neutralizing 
low-pH compartments, such as chloroquine and ammonium chlo-
ride15. We, therefore, investigated whether autophagy contributed to 
the different levels of residual midbodies in NS-5 versus HeLa cells   
(Fig. 4a–c). Cells were treated for 3 days with either 10 µM chloro-
quine or 1 mM ammonium chloride (higher concentrations were 
toxic  for  NS-5  cells)  and  analysed  for  cell-associated  midbodies   
by immunofluorescence for CRIK. This revealed that in HeLa cells, 
inhibition of autophagy resulted in an up to twofold increase in 
the average level of residual midbodies per cell (Fig. 4d,e). In con-
trast, the low level of residual midbodies in NS-5 cells (as com-
pared with HeLa cells) was unchanged on inhibition of autophagy   
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Figure 2 | Velocity sucrose gradient centrifugation of midbodies released from various cell lines. Conditioned media from ns-5 (a,e), neuro-2a 
(b,f), Es-R1 (c,g) and P-19 (d,h) cells were obtained as in Fig. 1 and subjected to a single centrifugation step to collect the P1 and P2 membrane particles 
together, which were then subjected to velocity sucrose gradient centrifugation. (a–d) Aliquots of the gradient fractions (1/2 of total, fraction 1 = top 
of gradient) and pellets (P, 1/5 of total) were subjected to immunoblot analysis for CRIK and α-tubulin. The positions of molecular weight markers are 
indicated. (e–h) Quantification of CRIK (circles) and α-tubulin (triangles) immunoreactivity in the gradient fractions, expressed as percentage of total 
(sum of gradient fractions). Data are the mean of two independent experiments; bars indicate the variation of the individual values from the mean.ARTICLE
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(Fig. 4d,e). We also observed a small (though statistically not sig-
nificant) increase in residual midbodies in Neuro-2a cells on chlo-
roquine treatment (Fig. 4d,e).
Ultrastructural aspects of midbody-retention versus -release. The 
data described thus far, together with previous observations11,12,14,15,17, 
are consistent with the concept that there are two principal fates of the 
post-abscission midbody. One is retention by one of the two daugh-
ter cells, which predominates in cells such as HeLa, and in which the 
midbody is typically degraded by autophagy, hence the increase in 
residual midbodies on inhibition of autophagy. The other is release 
into the extracellular space, which predominates in cells such as 
NS-5, and in which the cell-associated stage of the midbody before 
release does not appear to involve low-pH autophagic organelles.
To gain further insight into the membrane processes underly-
ing the distinct fates of the midbody, we analysed the ultrastruc-
ture  of  cell-associated  and  released  midbodies  in  cells  differing 
in midbody-retention versus -release, using electron microscopy 
(EM). In HeLa (Fig. 5a–f), Neuro-2a (Fig. 5g–i) and NS-5 (Fig. 
5j–l)  cells,  midbodies  before  abscission  showed  the  characteris-
tic  morphology  of  their  cytoplasm,  the  clusters  of  microtubules 
that represent the remnants of the central spindle, and the elec-
tron-dense  core  in  the  centre  of  the  midbody  that  includes  the 
remnants  of  the  contractile  ring  (Fig.  5a,g,j;  for  serial  sections, 
see  Supplementary  Fig.  S1)4,31.  In  the  subsequent  investigation 
of  the  ultrastructure  of  cell-associated  versus  released  midbod-
ies, we shall use the term ‘midbody’ when both, its characteristic 
cytoplasmic components and the surrounding plasma membrane, 
are present. By contrast, we shall use the term ‘midbody matrix’  
for structures containing the characteristic cytoplasmic midbody 
components but lacking the surrounding plasma membrane.
In HeLa cells, the typical fate of the characteristic cytoplasmic 
midbody structures was to end up in autophagic vacuoles (Fig. 5c–f;   
for serial sections of Fig. 5f, see Supplementary Fig. S2a). In most 
instances, the ultrastructural analysis did not allow us to deter-
mine whether this fate involved autophagy of the midbody includ-
ing its plasma membrane (Fig. 5m, pathway 2) or just of the mid-
body matrix (Fig. 5m, pathway 1). In support of pathway 2, we did 
observe cases in which internalization of the midbody by one of 
the daughter cells was initiated before abscission (Fig. 5b; for serial   
sections, see Supplementary Fig. S2b).
In contrast, in NS-5 cells, the morphology of the midbody after 
abscission was distinct, consistent with its typical fate being the 
release into the medium (Fig. 5m, pathway 4). Thus, we frequently 
observed midbodies that protruded from the surface of one of the 
daughter cells (Fig. 5k) and, on serial sectioning, were found to be 
no longer connected to the other daughter cell (Supplementary Fig. 
S3a). Serial sections of midbodies protruding from the surface of 
one daughter cell and no longer connected to the other daughter cell 
are shown for ES-R1 cells in Supplementary Figs S4 and S5. More-
over, we frequently observed midbodies in the vicinity of the cell 
surface (Fig. 5l) that on serial sectioning were found to be no longer 
connected to any cell (Supplementary Fig. S3b). The ultrastructural 
appearance  of  both,  the  plasma  membrane-protruding  and  the 
cell-detached midbodies was reminiscent of the ‘aged’ midbodies 
released from neuroepithelial cells into the ventricular fluid17.
In Neuro-2a cells, the typical morphology of the midbody after 
abscission indicated both, its ending-up in an autophagic vacuole 
(Fig. 5h; Supplementary Fig. S6) and its being released into the 
medium (Fig. 5i; Supplementary Fig. S6). In general, microtubule 
structure  appeared  better  preserved  in  autophagic  vacuole-con-
tained than released midbodies. The ultrastructural analysis did not 
allow us to determine whether the pathway to autophagic vacuoles 
occurred without cell detachment of the midbody (Fig. 5m, path-
ways 1 and 2) or after midbody-release followed by endocytosis 
(Fig. 5m, pathway 3).
Live imaging of midbody-retention versus -release. We sought to 
directly visualize midbody-retention versus -release by live imaging. 
To this end, we performed long-term time-lapse video microscopy 
on BAC-transgenic NS-5, Neuro-2a and HeLa cells expressing an 
MKLP-1–GFP fusion protein (Supplementary Fig. S7a). MKLP-1 is 
known to localize to the spindle midzone in anaphase and to con-
centrate at the midbody in telophase28,32, and the same was observed 
for  the  MKLP-1–GFP  fusion  protein  (Supplementary  Fig.  S7b).   
Accordingly,  in  MKLP-1–GFP  expressing  cells,  midbodies  could   
be  readily  identified  as  GFP-positive  dots  appearing  in  telophase   
(Supplementary Fig. S7c), which allowed monitoring their subsequent 
fate (retention versus release), notably after abscission (Fig. 6a–c).
Consistent with the abundant presence of midbodies in the con-
ditioned culture medium (Figs 1 and 3), NS-5 cells released mid-
bodies into the medium in the vast majority (≈90%) of cases (Fig. 
6a,d; Supplementary Movie 1). In contrast, HeLa cells almost always 
( > 90% of cases) showed midbody-retention (Fig. 6c,d; Supplemen-
tary Movie 2), defined as persistence of the cell-associated MKLP-
1–GFP dot over one cell cycle or its gradual disappearance within 
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the cell during the cell cycle, which presumably reflected its degra-
dation in autophagic vacuoles (Fig. 5). Midbodies retained by HeLa 
cells that persisted for longer than one cell cycle were not released 
during the next cell cycle but rather contributed to the presence of 
multiple midbodies retained by these cells (Fig. 6c; Supplementary 
Movie 2), as observed previously by other investigators12,14. Inter-
estingly, Neuro-2a cells showed an intermediate behaviour, with 
midbody-release occurring in half of the cases (Fig. 6b,d; Supple-
mentary Movie 3). This is consistent with the intermediate values 
obtained for Neuro-2a cells compared with NS-5 and HeLa cells 
with regard to the abundance of midbodies in conditioned culture 
medium (Fig. 1) and the increase in residual midbodies in cells on 
inhibition of autophagy (Fig. 4d,e).
The  temporal  relationship  between  abscission  and  midbody-
release is unknown. We exploited the present live imaging system to 
determine this temporal relationship for NS-5 and Neuro-2a cells. In 
both cell types, midbody-release did not coincide with, but occurred 
significantly after, abscission (Fig. 6e). For NS-5 cells, the average lag 
period between abscission and midbody-release was more than half 
an hour, with abscission having occurred ~100 min after appearance 
of the MKLP-1–GFP midbody dot. For Neuro-2a cells, the time 
periods from midbody appearance to abscission, and from abscis-
sion to release, were even longer (~200 min each) (Fig. 6e).
As to the fate of the released midbodies, we noticed that MKLP-
1–GFP containing midbodies released from Neuro-2a cells, after a 
period of movement in the intercellular space, contacted other Neuro-
2a cells (Supplementary Fig. S8a). Consistent with this, we observed, 
by EM, midbodies that had been released into the ventricular fluid 
to be located in the immediate vicinity of coated pits at the ventricu-
lar surface of mouse E10.5 neuroepithelial cells (Supplementary Fig. 
S8b). Immunogold labelling for prominin-1 revealed the budding of 
small membrane vesicles from such midbodies that apparently were 
internalized via coated pits (Supplementary Fig. S8c,d).
Midbody-release increases on stem cell differentiation. The present 
evidence for midbody-release in various cell culture systems provided 
an opportunity towards obtaining clues as to the significance of mid-
body-retention versus -release. Specifically, we noticed that the cells 
showing significant midbody-release all are either stem cells capable 
of undergoing differentiation (NS-5, CGR8-NS, ES-R1, HSCs)29,33,34 
or tumour-derived cell lines still responsive to differentiating agents 
(Neuro-2a,  P-19,  SH-SY5Y)35–37.  We,  therefore,  used  NS-5  cells, 
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Figure 4 | Midbody-retention in relation to cell growth rates and in response to inhibition of autophagy. (a,b) Immunofluorescence (red) of ns-5, 
neuro-2a and HeLa cells for CRIK (a) and mKLP-1 (b); nuclei were counterstained with Hoechst (blue). Arrowheads indicate residual midbodies in 
cells; note the greater frequency of residual midbodies in HeLa over neuro-2a over ns-5 cells. scale bars, 20 µm. (c) ns-5, neuro-2a, HeLa, Es-R1, 
P-19 and 3T3 cells were cultured under conditions allowing exponential growth. The average number of residual midbodies per cell, determined by 
CRIK immunofluorescence/Hoechst staining as in (a) and counted for at least 100 cells per cell line and experiment, is plotted as a function of cell 
doubling time. Data are the mean of three independent experiments; bars indicate s.d. P-values for residual midbodies per cell: ns-5 versus all other 
cells  < 0.001 except P-19 ( < 0.05); neuro-2a versus HeLa and Es-R1  < 0.01; 3T3 versus HeLa and Es-R1  < 0.05 (student’s t-test). (d,e) ns-5, neuro-2a 
and HeLa cells were grown for 3 days in the absence (control, con) and presence of 10 µm chloroquine (Cq) or 1 mm ammonium chloride (nH4Cl). (d) 
Immunofluorescence (red) for CRIK; nuclei were counterstained with Hoechst (blue). Arrowheads indicate residual midbodies in cells; note the greater 
frequency of residual midbodies in HeLa, but not ns-5, cells on inhibition of autophagy. scale bars, 20 µm. (e) Quantification of the average number of 
residual midbodies per cell, determined by CRIK immunofluorescence/Hoechst staining as in (d) and counted for at least 100 cells per cell line, condition 
and experiment. Data are the mean of three independent experiments each; bars indicate s.d. *P=0.03; ***P < 0.001 (Welch two-sample t-test).ARTICLE

nATuRE CommunICATIons | DoI: 10.1038/ncomms1511
nATuRE CommunICATIons | 2:503 | DoI: 10.1038/ncomms1511 | www.nature.com/naturecommunications
© 2011 Macmillan Publishers Limited. All rights reserved.
Neuro-2a cells and HSCs to explore whether switching cells from 
proliferation to differentiation affects the extent of midbody-release.
We  first  compared  midbody-release  from  NS-5  cells  grown 
under  expansion  conditions  to  that  from  NS-5  cells  induced  to 
undergo neuronal differentiation, performing immunoblot analysis 
for CRIK after isolation of P2 particles from the respective condi-
tioned medium. This showed that from 8 h after induction of dif-
ferentiation  onwards,  the  amount  of  CRIK-positive  P2  particles 
released into the medium increased with a concomitant decrease in 
cell-associated CRIK (Fig. 7a). In quantitative terms, differentiating 
NS-5 cells released almost half of the total CRIK into the medium 
in association with P2 particles during 20 h (Fig. 7b). Concomitant 
with  the  increase  in  midbody-release  during  differentiation,  the 
proportion of NS-5 cells remaining in the cell cycle, as indicated by 
BrdU incorporation, decreased (Fig. 7c).
We then used the MKLP-1–GFP-expressing Neuro-2a cells to 
compare  midbody-retention  versus  -release  by  time-lapse  video 
microscopy of control cells and cells induced to undergo neuronal 
differentiation by serum reduction and addition of retinoic acid 
(Fig.  7d;  Supplementary  Movie  4)36.  Neuronal  differentiation  of 
Neuro-2a cells resulted in a twofold increase in midbody-release at 
the expense of midbody-retention (Fig. 7e). In addition, differentia-
tion appeared to reduce the time period between formation of the 
MKLP-1–GFP midbody dot and abscission, and between abscission 
and midbody-release (Fig. 7f).
As a third system to investigate whether switching cells from 
proliferation to differentiation affects the extent of midbody-release, 
we compared HSCs grown under control, that is proliferating, con-
ditions  to  HSCs  treated  for  24 h  with  phorbol-12-myristate-13-
acetate  (PMA),  which  is  known  to  induce  their  differentiation34  
(Fig. 7g–m). Phorbol ester treatment resulted in a small decrease in 
cell numbers, as indicated by quantification of nuclei (Fig. 7g,h), but 
caused a massive decrease of cycling HSCs, as indicated by quantifi-
cation of phosphohistone H3-positive cells (Fig. 7g,i). Accordingly, 
m
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Figure 5 | EM analysis of midbody-retention and autophagy versus midbody-release. (a–f) HeLa cells, (g–i) neuro-2a cells, (j–l) ns-5 cells. (a,g,j) 
midbodies at telophase. (b) midbody matrix partially engulfed by one of the daughter cells, before abscission. (c,d) Residual midbodies in intracellular 
vacuoles of HeLa cells treated with 20 µm chloroquine for three days before fixation; note the longitudinal microtubule bundles. (e,f) Residual midbodies 
with longitudinal microtubule bundles in intracellular vacuoles of untreated HeLa cells. (h) Residual midbody with cross-sectioned microtubules in an 
intracellular vacuole of an neuro-2a cell. (k) midbody protruding from the surface of an ns-5 cell after abscission. (i,l) midbodies released from neuro-
2a (i) and ns-5 (l) cells. nuclei are indicated by asterisks in (e,f,h,i,k,l); asterisk in (b) indicates chromatin, dotted line membrane; scale bar for (a–l), 
200 nm. (m) Cartoon illustrating potential fates of the midbody after abscission (top). Pathway 1: the midbody matrix (brown diamond) without midbody 
plasma membrane (blue) is engulfed by an autophagic vesicle (green). Pathway 2: the midbody (matrix plus plasma membrane) remains attached to one 
daughter cell and is internalized followed by fusion with an autophagic vesicle. Pathway 3: the midbody (matrix plus plasma membrane) is released from 
the cell by a second, abscission-like, fission event, followed by endocytosis by the same (3c, d) or another (not illustrated) cell. Pathway 4: the midbody 
(matrix plus plasma membrane) is released from the cell into the extracellular space by a second, abscission-like, fission event, which may be followed by 
midbody decomposition (4d).ARTICLE     
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the number of midbodies released into the medium, as indicated 
by the quantification of CRIK-positive particles in the P1 and P2 
pellets, was similar for phorbol-ester-treated HSCs compared with 
proliferating HSCs when expressed per dish (Fig. 7j), but dramati-
cally increased when expressed per mitotic HSC observed at the end 
of culture (Fig. 7k). Consistent with this, the absolute amount of P2-
associated CRIK immunoreactivity was similar for phorbol-ester-
treated  HSCs  compared  with  proliferating  HSCs  (Fig.  7l).  Note   
that most of the CRIK immunoreactivity in the P1 pellet of control 
HSCs (Fig. 7l) reflected non-attached cells rather than P1 particles 
(Fig. 7g). In contrast, the amount of P2-associated CRIK immuno-
reactivity relative to cellular CRIK immunoreactivity was increased 
threefold on phorbol ester treatment (Fig. 7l,m).
In quantitative terms, ~30 midbodies per mitotic HSC observed 
at the end of culture were released from phorbol-ester-treated HSCs 
during the 24 h period (Fig. 7k). Considering that, first, the cell cycle 
of HSCs under the present conditions is ~24 h (ref. 34) (J.K. and 
D.C., unpublished data), that is, the HSCs subjected to phorbol ester 
treatment underwent on average one round of cell division during 
the culture period, and, second, at any time, one of ~30 cycling 
HSCs was in mitosis (Fig. 7h,i, con), these data imply that essentially 
every cell division of phorbol-ester-treated HSCs was accompanied 
by midbody-release. As the vast majority of cell divisions of phor-
bol-ester-treated HSCs give rise to post-mitotic cells (Fig. 7i), this, 
in turn, is consistent with the notion that terminal HSC divisions 
are associated with midbody-release.
Collectively, these observations with three distinct cell systems 
indicate that switching cells from proliferation to differentiation 
affects the extent of midbody-release. Specifically, divisions of stem 
cells and differentiation-responsive tumour cells that result in the 
production of differentiated progeny, notably terminal divisions, are 
typically  followed  by  midbody-release,  whereas  midbody-release 
occurs less frequently after divisions producing daughter cells that 
remain in the cell cycle.
Role  of  the  abscission  machinery  in  midbody-release.  From 
a  mechanistic  point  of  view,  midbody-release,  like  abscission, 
involves  plasma  membrane  fission  and  hence  may  utilize  core 
a
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Figure 6 | Live imaging of the dynamics of midbody-retention versus -release in various cell lines. BAC-transgenic cell lines expressing mKLP-1–GFP 
were analysed by time-lapse video microscopy for up to 48 h. (a–c) selected images (combined bright-field and fluorescence) of ns-5 cells (a, 6-min 
intervals, supplementary movie 1), neuro-2a cells (b, 15-min intervals, supplementary movie 3) and HeLa cells (c, 10-min intervals, supplementary  
movie 2); the time points are given as h:min, with the first image shown taken at 6:00 (ns-5), 8:15 (neuro-2a) and 0:40 (HeLa), respectively, and 
arbitrarily set to 0:00. Large arrowheads, midbodies destined to be retained; arrows, midbodies destined to be released; arrows with asterisk, released 
midbodies; small white arrowheads, midbody emerging at second telophase. Yellow frame (m), rounded-up mitotic cell; blue frame (T), cell in telophase 
with emerging midbody; red frame (A), abscission (double red arrowheads, the last image before the abscission event is shown); green frame (R), 
midbody-release. scale bars, 10 µm. (d) Quantification of midbody-release events (light grey) versus midbody-retention events (dark grey), expressed 
as percentage of total (release plus retention) events in a given experiment. Data are the mean of 3 independent experiments; bars indicate s.d. number 
of total events in all experiments together: ns-5, 60; neuro-2a (n-2a), 50, HeLa, 51. *P=0.02 ns-5 versus neuro-2a, **P=0.01 neuro-2a versus HeLa, 
***P < 0.001 ns-5 versus HeLa (student’s t-test). (e) Determination, for the midbody-release events, of the average time between telophase (blue T and 
arrows, arbitrarily set to 0 min), abscission (red A and arrows) and midbody-release (green R and arrows) observed in a given experiment. Data are the 
mean of 3 independent experiments; bars indicate s.d. Asterisks, time from telophase to abscission, and from abscission to midbody-release, between 
ns-5 and neuro-2a cells, P-value  < 0.05. number of total midbody-release events in all experiments together: ns-5, 52 (the value for abscission was 
determined from 34 events); neuro-2a, 32 (student’s t-test).ARTICLE
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components  of  the  abscission  machinery.  The  endosomal  sort-
ing complex required for transport family member, the apopto-
sis-linked gene 2 interacting protein X (Alix), has previously been 
shown to be involved in two plasma membrane fission processes, 
the pinching-off of membrane-enveloped virus particles from the 
plasma  membrane,  and  abscission38,39.  Alix  has  been  shown  to 
interact with the centrosomal protein 55 (Cep55) and the tumour-
suppressor gene 101 (Tsg101) in the latter process40. Given that 
these three proteins are essential components of the abscission 
machinery, we performed knockdown in NS-5 cells (Fig. 8a,b) 
and MKLP-1–GFP-expressing Neuro-2a cells (Fig. 8c–n) by RNAi 
using small interfering RNAs (siRNAs), and analysed the effects 
on  midbody-release  versus  retention  by  immunoblotting  for 
CRIK (Fig. 8a,b,d,e) or by quantifying the number of cell-retained 
midbodies and cells using automated image analysis (Fig. 8f–j), 
respectively.
On knockdown of Alix, the amount of CRIK-positive P2 par-
ticles released from NS-5 cells into the medium decreased signifi-
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Figure 7 | Differentiation promotes midbody-release. (a–c) ns-5 cells were cultured in either expansion medium or medium inducing neuronal 
differentiation, and analysed at the indicated times. (a) CRIK immunoblot of cells (1/10 of total) and P2 pellet of conditioned medium (1/2 of total).  
(b) Quantification of P2 CRIK immunoblots (circles, expansion; triangles, differentiation) as in (a); total, sum of cells plus P2. mean of three independent 
experiments; bars, s.d. P=12 h, ***P < 0.001; 20 h, **P=0.004 (student’s t-test) expansion versus differentiation. (c) Percentage of Brdu-labelled cells 
after 30-min pulse (circles, expansion; triangles, differentiation). mean of two independent experiments; bars, variation of individual values from mean. 
(d–f) Time-lapse video microscopy of control (con) and retinoic acid- (RA) treated mKLP-1–GFP transgenic neuro-2a cells. (d) selected images (15-
min intervals, supplementary movie 4) of cell division (RA); time, h:min; 0:00, beginning of time-lapse. Arrows, midbody; asterisk, release. Yellow m, 
mitotic cell; blue T, telophase; red A, abscission (red arrowheads); green R, midbody-release. scale bar, 10 µm. (e) Percentage of midbody-release (light 
grey) versus midbody-retention (dark grey) events. mean of 3 independent experiments; bars, s.d. Total events: con 50, RA 69. Con versus RA *P < 0.05 
(student’s t-test). (f) Time between telophase (blue T, arbitrarily set to 0 min), abscission (red A) and midbody-release (green R). mean of three 
independent experiments; bars, s.d. Total midbody-release events: con 13, RA 39. (g–m) Analyses of HsCs and P1/P2 pellets of conditioned medium after 
24-h culture on msCs without (control, con; dark grey) or with PmA (light grey). (g) Phosphohistone H3 immunofluorescence (yellow) of cells and CRIK 
immunofluorescence (red) of P1/P2; Hoechst (blue), nuclei. scale bars, 20 µm and 1 µm (inset). (h) Cells per mm2 (nuclear counts in 0.2–0.6 mm2); mean 
of four cultures (duplicates from two separate donors); bars, s.d. (i) mitotic cells per mm2 (phosphohistone H3-positive nuclei in 0.6–0.7 mm2); mean of 
two separate donors; bars, variation of individual values from mean. (j,k) CRIK-immunoreactive particles in P1/P2 (counting 3–5 random fields as in (g)), 
expressed per mm2 (j) or per phosphohistone H3-positive cell (k); mean of two independent experiments; bars in (j), variation of individual values from 
mean. (l) CRIK immunoblots of cells (C, 1/10 of total) and total P1/P2. Bottom PmA blot, longer exposure to normalize cells to control. (m) Quantification 
of P2 CRIK immunoblots as in (l); total, sum of cells plus P1-3. mean of five values (two donors, duplicate and triplicate); bars, s.d. **P < 0.01 (student’s 
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cantly in comparison to control (Fig. 8a,b). Similarly, knockdown 
of Alix, Tsg101 or Cep55 in Neuro-2a cells significantly reduced the 
amount of CRIK in the P1 and P2 pellets (Fig. 8c–e).
Accordingly,  the  number  of  residual  midbodies  per  cell  was 
significantly increased on Alix, Tsg101 or Cep55 knockdown in 
Neuro-2a cells compared with control cells (Fig. 8f,g,i). By contrast, 
the number of cells (Fig. 8j) was not significantly altered on RNAi 
for Alix compared with control, suggesting that abscission was not 
impaired under the present conditions of Alix knockdown. How-
ever, knockdown of Tsg101 or Cep55 resulted in a slight (though 
not statistically significant) reduction in cell number, potentially 
due to abscission defects. Together, the immunoblotting (Fig. 8a–e) 
and immunofluorescence (Fig. 8f–j) data imply that core compo-
nents of the abscission machinery, notably the endosomal sorting 
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(o) Hypothetical relationship between midbody-retention versus -release and differentiation. DC, differentiated cell; mb, midbody; PC, proliferating cell.ARTICLE
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complex required for transport-family member Alix, are also essen-
tial factors for midbody-release.
Midbody-release impacts on cell differentiation. The involvement of 
Alix, Tsg101 and Cep55 in midbody-release allowed us to test whether 
knockdown of these proteins would affect the responsiveness of cells 
to differentiating agents. To this end, we performed siRNA-mediated 
knockdown  in  MKLP-1–GFP-expressing  Neuro-2a  cells,  followed 
by retinoic acid-induced differentiation (Fig. 8k–n). Under control 
conditions (Fig. 8k), Neuro-2a cells exposed to retinoic acid typically 
developed a bipolar morphology, with processes ranging in length 
from 11 to 16 µm and containing immunoreactivity for βIII-tubulin, 
a neuronal marker (Fig. 8k,m,n). When cells were subjected to Alix 
RNAi, the average length of processes doubled, ranging from18 to 
29 µm (Fig. 8l,m). A similar effect was observed on Tsg101 or Cep55 
knockdown, although the average length of processes was much more 
variable and thus its increase not statistically significant (Fig. 8l,m). 
In addition, especially in the case of Cep55, the number of processes 
per cell was increased on knockdown, with the appearance of large 
multinucleated cells that occasionally developed a massive outgrowth 
of highly branched processes (Fig. 8l). As an increase in the growth 
and branching of βIII-tubulin–positive processes of Neuro-2a cells is 
indicative of their neuronal differentiation41, we conclude that knock-
down of Alix, Tsg101 or Cep55, which results in reduced midbody-
release (Fig. 8c–j), also results in increased responsiveness of these 
cells to a differentiation stimulus.
Discussion
The present study constitutes, to the best of our knowledge, the first 
quantitative analysis of midbody-release from various cell types. 
This analysis provides insight into four aspects regarding the release 
process and its biological significance. First, by comparing differ-
ent  cell  types  under  defined  culture  conditions,  we  corroborate 
the existence of two alternative pathways with regard to the fate of 
the post-abscission midbody, that is, retention by the daughter cell 
that inherited it, and release into the extracellular space. The use of 
these two pathways differed dramatically between distinct cell types 
and was substantially influenced by the specific growth conditions. 
Remarkably, midbody-release was highest in neural, haematopoietic 
and embryonic stem cells and much lower in cancer-derived and 
immortalized cells. Among the cancer-derived and immortalized 
cells, it is noteworthy that cell lines still responsive to differentiat-
ing agents (Neuro-2a, P-19, SH-SY5Y) showed a greater extent of 
midbody-release than cell lines lacking this property (for example, 
HeLa, CHO and HEK293). Although further analyses are clearly 
required, the present observations raise the exciting possibility that 
the extent of midbody-release may be related to the differentiation 
potential of stem and cancer cells.
Second, and in line with this possibility, there was an increase in 
midbody-release at the expense of midbody-retention when NS-5, 
Neuro-2a cells and HSCs were induced to shift from proliferation to 
differentiation, that is, to switch their mode of division with regard 
to the fate of the resulting progeny. In fact, quantification of the 
number of midbodies released from HSCs on differentiation in rela-
tion to the number of cell divisions was consistent with the notion 
that essentially all divisions giving rise to two post-mitotic daughter 
cells are accompanied by midbody-release (Fig. 8o). The observa-
tion that withdrawal from the cell cycle of NS-5 cells subjected to 
neuronal differentiation is followed by midbody-release supports 
this notion. In this context, one may speculate about a causal role 
of midbody-release in cell differentiation. For example, some of the 
membraneous and cytoplasmic components that cluster at the mid-
body4,17,42–44 may influence the balance between proliferation and 
differentiation in favour of the former, and, hence, their irreversible 
removal via midbody-release may contribute to the differentiation 
of stem and cancer cells.
Third, although the timing of midbody-release was found to 
be different from abscission, the molecular machinery underly-
ing midbody-release was related to abscission. Dissection of the 
midbody-release process by time-lapse video microscopy of indi-
vidual cell divisions revealed that midbody-release did not occur 
concomitant  with  abscission.  Rather,  we  observed  a  significant 
lag  period  between  abscission  and  midbody-release  that  varied 
between the different cell types studied (NS-5, Neuro-2a). This lag 
period was the shorter the more frequently cells used midbody-
release rather than retention (that is, shorter lag in NS-5 compared 
with Neuro-2a cells, and in retinoic acid-treated compared with 
control Neuro-2a cells). Importantly, the length of this lag period 
was not proportional to the duration of the cell cycle, as Neuro-2a 
cells showed a longer lag period but shorter cell cycle than NS-5 
cells. Furthermore, knockdown of Alix, which is known to func-
tion  in  abscission39,45,  or  of  its  interaction  partners  Tsg101  and 
Cep55 (ref. 46), resulted in a decrease in midbody-release and an 
increase in midbody-retention. This supports the view that mid-
body-release, though regulated independently from abscission, is 
mechanistically related to the latter membrane fission process. In 
this context, it may be worthwhile to investigate whether CENP-A 
depleted HeLa cells, which have been reported to exhibit very long 
and thin midbodies47, perhaps exhibit higher midbody-release than 
the HeLa cells analysed here.
Fourth, the identification of Alix, Tsg101 and Cep55 as com-
ponents of the machinery mediating midbody-release offered an 
approach to explore a possible link between midbody-release and 
differentiation. Indeed, knockdown of these proteins in Neuro-2a 
cells not only increased midbody-retention but also the responsive-
ness of these cells to a differentiation stimulus, as indicated by the 
enhanced neurite outgrowth on retinoic acid treatment. These obser-
vations are consistent with the hypothesis that, in a proliferating cell 
capable of responding to a differentiation stimulus, the switch from 
proliferation to differentiation, notably to terminal divisions of pro-
genitor cells, is accompanied by midbody-release (Fig. 8o). Thus, 
the data presented in the present study provide a basis to further 
investigate how midbody-retention versus -release and stem/cancer 
cell proliferation versus differentiation are interrelated.
Methods
Cell lines. Neuro-2a, P-19, SH-SY5Y, HeLa, NIH-3T3, CHO, HEK293 and L929 
cells were grown in DMEM supplemented with 10% FCS; MCF-7 were grown in 
DMEM supplemented with 10% FCS and 1×non-essential amino acids (Sigma); 
MCF-10A were cultured as described48; ES-R1 (ref. 30) in DMEM supplemented 
with 15% FCS, 2 mM l-glutamine, 1× non-essential amino acids, 100 µM mercap-
toethanol and 1,000 U ml − 1 LIF (ESGRO, Millipore); NS-5 and CGR8-NS cells in 
NS cell expansion medium (containing 10 ng ml − 1 EGF and 10 ng ml − 1 FGF-2) as 
described49. All cell lines were maintained at 37 °C and 5% CO2. The MKLP-1 BAC-
transgenic cell lines are described in the Supplementary Methods.
Culture of cell lines. For biochemical experiments, cells were plated on 3-cm 
dishes at 50,000 (HeLa, P-19), 100,000 (Neuro-2a, 3T3), and 200,000 (NS-5, ES-
R1, CHO, HEK293, MCF-7, MCF-10A and L929) cells per dish in 2 ml medium. 
To determine cell doubling time, cells after 8, 20, 32, 48 and 68 h of growth were 
removed from the dish and suspended in 1 ml trypsin/EDTA/HBSS, and counted 
(Kova Glasstic slides). Cell doubling times were calculated from the exponential 
phases of the growth curves obtained. For some cell lines (CHO, HEK293, MCF-7, 
MCF-10A and L929), doubling time was estimated by counting cells 24 h after 
plating and just before centrifugation of the conditioned medium. In the case of 
SH-SY5Y and CGR8-NS cells, doubling time was estimated from the time that cells 
split 1:4 or 1:8 and re-plated required to reach the original state of subconfluency.
To obtain conditioned medium containing released midbodies, cells were 
grown for 2 rounds of doubling (Fig. 1), and 1.5 ml of the conditioned medium 
was collected and subjected to differential centrifugation. Following removal of the 
remaining medium, cells were lysed on the dish in 200 µl of 2× concentrated SDS 
sample buffer.
For comparing different culture formats, NS-5 cells were plated at 100,000 cells 
on a six-well plate in 1.5 ml and at 550,000 cells on a 10-cm dish in 10 ml medium. 
After 48 h, conditioned medium was subjected to differential centrifugation. Cells 
on six-well plates were lysed in 100 µl, and cells on 10-cm dishes in 550 µl, of 2× 
SDS sample buffer.ARTICLE     
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For live imaging, cells were plated on gelatin-coated four-well or Lab-Tek 
eight-well chambered coverglass, at a lower density than for biochemical experi-
ments to facilitate monitoring of individual cells, that is 10,000 cells per cm2 (NS-5, 
Neuro-2a) or 5,000 cells per cm2 (HeLa) in 1 ml and 0.5 ml, respectively, of NS cell 
expansion medium (NS-5) or DMEM supplemented with 10% FCS (Neuro-2a, 
HeLa). After 12–24 h, cells were subjected to time-lapse video microscopy.
Primary cell culture. HSCs and MSCs were collected from healthy donors after in-
formed consent and approval by the local ethics committee. Isolation of MSCs was 
performed as described50. CD34 +  MACS-immunoisolated HSCs (300,000 cells) 
from leukapheresis products50 were cultured either on fibronectin-coated six-well 
plates or on MSCs on fibronectin-coated six-well plates, in 3 ml of HSC medium 
(serum-free medium containing early acting cytokines (50 ng ml − 1 stem cell factor, 
50 ng ml − 1 fetal liver tyrosine kinase-3 ligand, 15 ng ml − 1 interleukin-3)) at 37 °C in 
a humidified 5% CO2 atmosphere34,50.
To obtain conditioned medium, cells were grown for 5 days, and 1.5 ml of the 
conditioned medium was subjected to differential centrifugation. Cells were lysed 
on the dish in 200 µl of 2× concentrated SDS sample buffer.
Inhibition of autophagy. Cells were plated on coverslips in 3-cm dishes at 50,000 
(HeLa) or 200,000 (Neuro-2a, NS-5) cells per dish in 2 ml medium containing 
10 µM chloroquine (Sigma) or 1 mM NH4Cl, as indicated. After 3 days of growth, 
cells were fixed and subjected to immunofluorescence.
Differentiation of cell lines. NS-5 cells were plated on polyornithine-/laminin-
coated four-well dishes at 50,000 cells per well in 1 ml NS cell expansion medium. 
After 15–20 h, the medium was changed to 1 ml of either NS cell expansion 
medium or medium inducing neuronal differentiation (NS cell expansion medium 
containing in addition B-27 supplement (Invitrogen) but only 5 ng ml − 1 FGF and 
lacking EGF)49. Conditioned medium was collected 30 min after medium change 
(0 h time point) or 2, 4, 8, 12 and 20 h after the 0 h time point, followed by dif-
ferential centrifugation. Cells were lysed on the dish in 100 µl of 2× concentrated 
SDS sample buffer.
In BrdU-labelling experiments, NS-5 cells were plated on coverslips and 
cultured as above, incubated in the presence of 50 µM BrdU for 30 min before the 
indicated time point, fixed and subjected to BrdU immunofluorescence.
Neuro-2a cells were plated on gelatin-coated Lab-Tek four-well or eight-well 
chambered coverglass at 10,000 cells per cm2 in 1 ml and 0.5 ml, respectively, 
of DMEM supplemented with 10% FCS. After 15–20 h, the medium was either 
replaced with fresh medium (control) or with DMEM supplemented with 2% FCS 
and 20 µM retinoic acid (dissolved in dimethylsulphoxide (DMSO), final con-
centration 0.1%) to induce neuronal differentiation, followed by time-lapse video 
microscopy. In some experiments, Neuro-2a cells were first subjected to RNAi, as 
described below, followed by differentiation as above for another 2 days, fixation 
and TuJ-1 immunofluorescence.
Differentiation of HSCs. HSCs cultured for 3 days were washed with PBS and 
re-plated (24-well plates) either on fibronectin-coated coverslips or on MSCs 
on fibronectin-coated coverslips, at 300,000 cells per well in 1 ml of fresh HSC 
medium. Differentiation medium contained 160 nM PMA(dissolved in DMSO, 
final concentration 0.01%), whereas control HSC medium contained 0.01% DMSO 
only. Control dishes with MSCs only indicated lack of contribution of MSCs to 
the results obtained. Cells on coverslips were kept in control or differentiation 
HSC medium for 24 h (ref. 34). Conditioned medium was collected, followed by 
differential centrifugation. Cells were lysed on the dish in 100 µl of 2× concentrated 
SDS sample buffer.
Time-lapse video microscopy. Cells on chambered coverglass were imaged with 
a Zeiss Axiovert 200M inverted fluorescence microscope equipped with a motor-
ized stage and incubator, humidifier and carbon dioxide supply (Visitron Systems) 
to maintain cell culture conditions. Bright-field and fluorescence images were 
acquired using a C-Apochromat 40× water immersion objective (NA 1.4) and re-
corded with a Roper Scientific CoolSNAP ES CCD camera using MetaMorph soft-
ware. For fluorescence, 8–12 z-planes with 0.8–1.5 µm steps were collected at any 
given time point. Multiple (10–30) fields were imaged in parallel per experiment, 
using 5–15 min intervals for up to 48 h. In the case of neuronal differentiation of 
Neuro-2a cells, time-lapse video microscopy was started about 1 h after addition of 
the retinoic acid-containing medium.
RNAi. NS-5 cells (six-well plates) were transfected with 250 nM Alix siRNA 
(Ambion, 5′-GAGGUAUUAUGAUCAGUUTT-3′) or negative control siRNA 
(Ambion) using Amaxa technology (Lonza, program FP-100, buffer SG). Medium 
was changed after 1 day and conditioned for 24 h before centrifugation.
RNAi of Neuro-2a cells was performed in either an automated manner using a 
Tecan Freedom Evo 200 liquid handling station (A.W.E., A.-M.M., M.B., A.L. and 
W.B.H., unpublished results), or conventionally. For automated RNAi, MKLP-1– 
GFP transgenic Neuro-2a cells were plated on poly-l-lysine-coated 384-well  
plates in a final volume of 50 µl at 400 cells per well, with each well containing  
0.8 µl Interferin (PolyPlus Transfection) and 10 nM siRNA (Invitrogen, Stealth  
RNAi). For conventional RNAi, transfections in 24- and 6-well plates were  
scaled up accordingly (24-wells, 5,000 cells, 3.1 µl Interferin, 0.4 ml final volume 
per well; 6-wells, 50,000 cells, 11 µl Interferin, 1.75 ml final volume per well). 
Sequences of siRNA oligos were as follows: Alix, 5′-CGGACCUUAAGGAUCU 
GGAUCCUAU-3′, 5′-UCCAGACUGUCGACCAGCUGAUAAA-3′, Tsg101,  
5′-CCAGGCAGAGCUUAAUGCCUUGAAA-3′, 5′-CCCAGUGCGUUAU 
CGAGGUAAUAUA-3′, Cep55, 5′-UGUCUUCAAGAAGUCCCAAAGAUUU-3′, 
5′-GGAACAGCAGAUGCAGGCAUGUACU-3′, negative control siRNA,  
5′-UUCCUCUCCACGCGCAGUACAUUUA-3′.
Cells in 384-well plates were fixed after 3 days of RNAi and stained with 
Hoechst 33342. Automated image acquisition was performed using a BD pathway 
855 microscope with ×10 objective. Cells in 24-well plates were subjected to RNAi 
for 3 days and then received fresh medium containing reduced serum and retinoic 
acid to induce differentiation. Cells in 6-well plates were subjected to RNAi for  
3 days followed by immunoblot analysis of cells and medium.
Image analysis and quantification. Image processing and analysis was done using 
ImageJ and the ImageJ distribution Fiji (http://pacific.mpi-cbg.de/wiki/index.php/
Fiji). Z-stacks of images were projected into one plane (maximum intensity projec-
tion). Cell-retained midbodies were counted in maximum intensity projections of 
cells co-stained for α-tubulin to outline the cell borders.
In time-lapse video microscopy, telophase cells were defined by the appear-
ance of GFP-positive midbodies. Severing of midbody-bridges, accompanied with 
a midbody displacement, was taken to indicate abscission events. The midbody 
of a given cell was followed and scored as released when outside the cell, and as 
retained when the cell entered the next mitosis with the midbody inside, or when 
the GFP faded gradually (confirmed by analysing the GFP channel alone).
Images of knockdown and control cells were analysed with CellProfiler 2.0 
software (The BROAD institute) to determine the number of cells (nuclei) and 
cell-retained midbodies. Neurite length and number of retinoic acid-differenti-
ated Neuro-2a cells immunostained with TuJ-1 were determined using the Simple 
Neurite Tracer plug-in of Fiji.
Statistical analysis. Statistical analysis was performed in ‘R’ statistical program-
ming environment and Excel (Microsoft). Statistical significance was calculated 
using Student’s t-test or Welch two-sample t-test. 
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